L. Tan

发表

Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities.

S. Knapp, N. Gray, Yanke Liang, 2020, Cell chemical biology.

Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities

S. Knapp, N. Gray, Yanke Liang, 2020, bioRxiv.

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.

P. Sorger, R. Everley, S. Knapp, 2019, Cell chemical biology.

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase

N. Gray, Qingsong Liu, Xianming Deng, 2015, PloS one.

Development of Selective Covalent Janus Kinase 3 Inhibitors.

Kwok-Kin Wong, N. Gray, S. Ficarro, 2015, Journal of medicinal chemistry.

Identification of a potent and selective covalent Pin1 inhibitor

N. Gray, S. Ficarro, J. Marto, 2020, Nature Chemical Biology.

Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo.

N. Gray, S. Hellwig, T. Smithgall, 2018, ACS chemical biology.

Abstract 2757: Discovery and characterization of covalent Pin1 inhibitors targeted to an active site cysteine

N. Gray, J. Marto, H. Seo, 2019, Cancer Chemistry.

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

D. Lauffenburger, P. Sorger, N. Gray, 2017, Bioorganic & medicinal chemistry.

Generation of a chemical genetic model for JAK3

J. Reményi, N. Gray, Jinhua Wang, 2021, Scientific Reports.

Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).

P. Jänne, N. Gray, Yang Gao, 2018, Journal of medicinal chemistry.

Essential Role for IKKβ in Production of Type 1 Interferons by Plasmacytoid Dendritic Cells*

P. Cohen, H. Choi, M. Peggie, 2012, The Journal of Biological Chemistry.

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Dennis L. Buckley, J. Bradner, N. Gray, 2017, Cell chemical biology.

Inhibition of IKKα by BAY61-3606 Reveals IKKα-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells

N. Gray, Tinghu Zhang, B. Strang, 2016, PloS one.

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.

R. Young, M. Meyerson, P. Hammerman, 2017, Cancer discovery.

Synergistic interactions with PI3K inhibition that induce apoptosis

John G Doench, W. Hahn, M. Cima, 2017, eLife.

Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.

N. Gray, Xianming Deng, T. Mitchison, 2012, ACS chemical biology.

Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development

N. Gray, Yanke Liang, Jinhua Wang, 2020, Cell.

Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

H. Seo, Xiao Zhen Zhou, K. Lu, 2018, Nature Communications.

Covalent Targeting of Fibroblast Growth Factor Receptor Inhibits Metastatic Breast Cancer

Michael K. Wendt, N. Gray, M. Wendt, 2016, Molecular Cancer Therapeutics.

RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade

Rachel G Liao, M. Meyerson, P. Hammerman, 2018, Molecular Cancer Therapeutics.

Ligand associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells

Rachel G Liao, P. Hammerman, Kwok-Kin Wong, 2014, Oncogene.

Cancer Biology and Signal Transduction Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR 2 Gatekeeper Mutation and NF 1 Loss

M. Meyerson, P. Hammerman, A. Dulak, 2014 .

Discovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Discovery of a Potent and Selective DDR 1 Receptor Tyrosine Kinase Inhibitor

Sam W. Lee, N. Gray, Qingsong Liu, 2013 .

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

K. Flaherty, Dennie T. Frederick, N. Gray, 2015, Cancer discovery.

DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors

N. Gray, M. Mohammadi, Xiaokun Li, 2014, ACS chemical biology.

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

M. Meyerson, P. Hammerman, N. Gray, 2015, ACS chemical biology.

EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.

W. Pao, N. Gray, D. Colvin, 2016, Cancer research.

EPHA2BlockadeOvercomesAcquired Resistance to EGFR Kinase Inhibitors in Lung Cancer

W. Pao, N. Gray, D. Colvin, 2016 .

Cancer Biology and Signal Transduction Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by Ddr2 Gatekeeper Mutation and Nf1 Loss

M. Meyerson, P. Hammerman, A. Dulak, 2022 .

Structural Mechanisms Determining Inhibition of the Collagen Receptor DDR1 by Selective and Multi-Targeted Type II Kinase Inhibitors

Kiki Chu, Peter Canning, Nathanael S. Gray, 2014, Journal of molecular biology.

Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)

P. Cohen, N. Gray, K. Westover, 2014, Journal of medicinal chemistry.

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Rachel G Liao, S. Gaudet, P. Jänne, 2014, Proceedings of the National Academy of Sciences.

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.

R. Tibshirani, I. Lossos, Y. Natkunam, 2016, Blood.

The IkappaB Kinase Family Phosphorylates the Parkinson’s Disease Kinase LRRK2 at Ser935 and Ser910 during Toll-Like Receptor Signaling

Patrick G. A. Pedrioli, P. Cohen, H. Cai, 2012, PloS one.

The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

N. Munshi, N. Gray, Jinhua Wang, 2021, Blood.

Studies of TAK 1-centered polypharmacology with novel covalent TAK 1 inhibitors

D. Lauffenburger, P. Sorger, N. Gray, 2017 .

Structure-guided development of covalent TAK1 inhibitors.

P. Sorger, N. Gray, K. Westover, 2017, Bioorganic & medicinal chemistry.

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Wei Zhang, P. Cohen, Shuai Liu, 2016, Blood.

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

P. Cohen, N. Gray, S. Treon, 2015 .

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth

N. Gray, S. Hellwig, T. Smithgall, 2017, PloS one.

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

Dana M. Brantley-Sieders, N. Gray, D. Colvin, 2014, The Journal of clinical investigation.

Catalytic domain plasticity of MKK7 reveals structural mechanisms of allosteric activation and new targeting opportunities

S. Knapp, N. Gray, Yanke Liang, 2020, bioRxiv.

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

N. Gray, S. Treon, Z. Hunter, 2015 .

EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

K. Flaherty, Dennie T. Frederick, N. Gray, 2015, Cancer discovery.